Ding Dong: The Doctor Will See You (at Home) Now
Increasingly, patients are able to receive treatment for hematologic malignancies from the comfort of home.
Call for ASH Clinical News Associate Editors (2024-2026)
Interested in being an associate editor of ASH Clinical News? Apply today!
Counting Her Chickens: Catherine C. Coombs, MD
In this edition, Catherine C. Coombs, MD, shares her passion for raising chickens and the surprising parallels she’s found between that and hematology.
Preexisting T-Cell Landscape May Determine Bispecific TCE Therapy Response in MM
Diagnostic Tool Can Help Discern MDS Among Patients With Cytopenias
The Often-Inexplicable Turns of a Career in Hematology
Andrew J. Cowan, MD
Dr. Cowan discusses the unpredictable journey that is a career in hematology. He addresses his experiences as a resident and fellow as well as interactions with mentors and the decision to pursue post-fellowship subspecialty training.
Assumptions of Patient Perceptions Create Unnecessary Barriers to Palliative Care
COVID-19 Bivalent Boosters Associated With Few Definitive Hematologic AEs
Most Read Articles
- Decitabine Yields Similar Survival Despite Superior Responses Versus HU in MP-CMML
- The United States of Medicine
- Consensus Guidelines Outline Treatment of ITP Related to SARS-CoV-2 Infection, Vaccination
- Machine Learning Algorithm Predicts Acquired Versus Inherited Bone Marrow Failure
- You Make the Call: When would you start phlebotomy for an asymptomatic patient with hemochromatosis?
Concurrent Pembrolizumab and AVD as Frontline Therapy in Untreated cHL
In patients with untreated classical Hodgkin lymphoma, concurrent use of pembrolizumab and the chemotherapy combination of doxorubicin, vinblastine, and dacarbazine was shown to be safe and effective without clinically significant treatment delays.
More Structure, Rigor Needed in Peripheral Blood Smear Training
Training in the review of peripheral blood smears in graduate hematology education should be done with a structured approach and with an emphasis on mastery of cases that could avert imminent clinical decompensation. Researchers convened a multi-institutional focus group to establish the core components of an assessment tool.
2022 ELN Genetic-Risk Stratification Does Not Predict Outcomes Better Than 2017 Stratification for Adults With AML
Researchers conducted an analysis of adult patients diagnosed with de novo AML. They analyzed the correlation between genetic-risk stratification and patient outcomes, compared performance of the stratifications in age and ethnicity cohorts, and evaluated the prognostic potential of additions to the criteria used by the 2022 ELN genetic-risk stratification.